Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty

Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February